For many cancer survivors, cannabis has become part of how they manage symptoms such as pain, nausea and anxiety. A new study from VCU Massey Comprehensive Cancer Center surveyed 395 cancer survivors and 62 cancer care providers  It found that while survivors and providers agreed on many aspects of medical cannabis, they differed in their awareness of potential risks and their comfort discussing it.

A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to phase I clinical trial results.

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

Elaine Jaffe, Laura Tafe and Daniel Sabath to be honored for lasting contributions to the molecular diagnostics community.

About The Study: In this cross-sectional temporal analysis, the marked reductions in excess mortality indicate meaningful progress achieved for several major cancer types through population-wide cancer control efforts. Persistent or worsening disparities in breast cancer and uterine corpus cancer and substantial residual disparities in prostate cancer highlight priorities for equitable interventions. These findings may guide more targeted and efficient cancer prevention and control strategies to further accelerate progress. 

LSU Health New Orleans has received a five-year, $3.1 million National Institutes of Health (NIH) grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.

A new Review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity. The authors propose that therapeutic activation of the ZBP1 pathway may transform immunologically "cold" tumors into "hot" tumors, offering new opportunities to overcome resistance to cancer immunotherapy.